drugset / Trial / NCT03208790

Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.

NCT03208790

Phase 2 Completed 48 enrolled Cairo University
RandomizedParallel-groupTriple-blindTreatment

Summary

The present randomized, controlled, parallel-grouped trial includes 48 patients (aged 18 to 75 years) suffering from oral potential premalignant lesions. Patients will be randomly assigned into 3 equal groups: Group A: Nigella Sativa buccal tablets group 10mg Group B: Nigella Sativa buccal tablets 5 mg Group C:Control group (placebo)

Timeline

Start
2017-09-30
Primary completion
2020-03-12
Completion
2020-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymoquinone Small molecule 5 mg Other
Subject Thymoquinone Small molecule 10 mg Other

Indications